Shares of the biotech firm Abivax saw a sharp decline following the release of phase 3 trial results for its inflammatory bowel disease drug, obefazimod. While the drug demonstrated strong efficacy in treating ulcerative colitis, a small number of cancer cases reported among participants have cast a shadow over the findings.
The trial data, released late Monday, revealed cases of basal cell carcinoma and squamous cell carcinoma in patients receiving high doses of obefazimod. Additionally, a few other cancer types, including prostate and breast cancer, along with colonic dysplasia, were noted in the high-dose group. This has apparently overshadowed the drug's positive performance in tackling the inflammatory condition.
Trial Efficacy and Adverse Events
The maintenance study, assessing obefazimod over 44 weeks, showed promising results for ulcerative colitis patients. The company reported infection rates comparable to placebo and, intriguingly, numerically more treatment-emergent adverse events leading to discontinuations in the placebo group than in either obefazimod dosage group.
Specifics of Reported Cases
Basal cell carcinoma: One case on placebo, two cases on the high dose.
Squamous cell carcinoma: One case on the low dose, two cases on the high dose.
Other cancers (high dose only): One case each of prostate cancer, breast cancer, and colonic dysplasia.
The biotech's stock experienced a significant collapse following the announcement, impacting its standing as a potential takeover target for larger pharmaceutical companies.
Future Outlook and Acquisition Speculation
Analysts have characterized obefazimod as a potentially best-in-class treatment for ulcerative colitis. However, the recent data has prompted caution. It is anticipated that potential buyers will likely await the full data set, expected in October, before making any acquisition decisions.
Read More: Danny Go Star Daniel Coleman's Son Isaac Dies After Cancer Battle
"The most likely scenario now is that Abivax will wait for the full data set, which is expected to be disclosed in October, to gain more granularity and confirm that the malignancies are not related to the treatment."
This cautious approach stems from a desire to further scrutinize the reported malignancies and ascertain any potential links to the drug itself. Abivax had reportedly been planning to raise funds following this data readout, a move that may now be complicated by the trial's reception.
